HQL: Attractive Outlook With Growth Of GLP-1 Market

I maintain a buy rating on abrdn Life Sciences Investors Fund (HQL), which trades at an 8.49% discount to NAV and offers a 12.6% yield. HQL is positioned to benefit from the accelerating GLP-1 market, with top holdings in high-growth biotech names and a portfolio heavily weighted to biotechnology. While total returns have been competitive, HQL's high distributions come at the expense of capital appreciation, making it best suited for income-focused investors.

Seeking Alpha • May 19, 2026

How To Invest $100,000 Today: 5 Strategies For Success

The market environment is challenging, to say the least. We discuss how one should invest in today's market. The article presents five different investment strategies, including a fixed-income strategy, high-income strategy, sleep-well-at-night strategy, growth-focused strategy, and the Near-Perfect Portfolio strategy. Selecting a strategy aligned with personal risk tolerance and sticking to it through cycles is critical for long-term success.

Seeking Alpha • Apr 25, 2026

10 Best CEFs This Month: Average Yield Of 10% (March 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and 10.8% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Mar 29, 2026

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Feb 28, 2026

How We're Playing ‘AI 2.0' For Big Dividend Payouts

If you're wondering whether the rally in tech stocks is fading, well, it is.

Forbes • Jan 31, 2026

HQL: Dividend Can Be Sustained Through 2026

abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL's income-focused strategy relies on net realized gains, supporting robust distributions but exposing NAV to downside risk in weak markets. Biotech dominates HQL's portfolio (82.7%), with top holdings like AMGN and REG, and no direct leverage, but interest rate sensitivity remains.

Seeking Alpha • Jan 28, 2026

HQL: Still Offers Attractive Value As Long As Interest Rates Decline

abrdn Life Sciences Investors remains a buy for high-yield seekers, offering a 10.1% dividend yield and diversified healthcare exposure. HQL trades at a 7.92% discount to NAV, with its share price historically benefiting from lower interest rates and sector growth initiatives. The fund's focus on income, option writing, and heavy biotech allocation limits long-term capital appreciation and has led to underperformance versus peers like THQ and THW.

Seeking Alpha • Nov 6, 2025

HQL: We Should Be Accumulating During The Weakness

HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to underperformance versus broader healthcare ETFs and higher sensitivity to sector weakness. Dividend coverage remains consistent despite recent earnings volatility, but distributions are not tax-efficient and rely on capital gains.

Seeking Alpha • Aug 21, 2025

CEF Insights: The Future Of Healthcare Investing

Groundbreaking AI-powered initiatives are set to transform the healthcare landscape, potentially revolutionizing cancer research and healthcare investing. Aberdeen Investments' four healthcare-focused closed-end funds meet various investor needs: THQ/THW for income and stability, HQH/HQL for growth and innovation exposure. Jason Akus, Portfolio Manager and Head of Healthcare Investments with Aberdeen Investments, gives insight into how new innovations may impact investment opportunities.

Seeking Alpha • Jun 25, 2025

HQL: Positive Outlook Due To Increased Healthcare Spending

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth outlook. Despite recent NAV declines and inconsistent income, HQL's performance is tied to macro conditions, not internal flaws, and should improve as the sector rebounds. HQL's diversified biotech-heavy portfolio, lack of leverage, and simple strategy offer stability and upside as healthcare spending rises.

Seeking Alpha • Jun 4, 2025